Why Nebraskans keep standing up for Head Start
As the recipient of Nebraska's largest Early Head Start-Child Care Partnership grant, we've made a promise: to show up with care, consistency and compassion, especially when families face the toughest of times. Our work with CRCC, CSI, Educare Lincoln and Educare of Omaha, Inc., brings more than 200 combined years of experience in serving Nebraska's children and their families.
The federally funded Head Start program is part of that promise, one that has received bipartisan support year after year. But in recent weeks, news broke about a federal budget proposal that would zero out funding for Head Start in 2026. It is impossible to state the impact this move would have on nearly 800,000 children and their families nationwide.
Congress has the power to decide what gets funded and what doesn't. That's where we need to act.
In Nebraska, Head Start funding supports the capacity for 5,653 eligible children, employing 2,187 staff in 179 child care centers across the state. These are not just numbers. These are real Nebraska children and families with real futures. And now, the funding to support them is at real risk.
For 60 years, this nationally recognized, locally rooted program has given our most vulnerable children a safe, developmentally rich environment to learn and grow while their parents work to achieve economic self-sufficiency. The National Head Start Association's 2025 Nebraska Head Start Profile shows that 4,137 parents of enrolled children were employed, in school or in job training, which would not be possible without reliable child care through Head Start.
Protecting Head Start is essential to the well-being of children, families, and communities. Any move away from this risks consequences we can't afford. We don't use these words lightly.
Head Start is a vital foundation for families working to build a better future. It offers reliable support for parents and strong, nurturing early education for children — along with meals, vision and hearing screenings, developmental assessments, and dental care.
Protecting Head Start means preserving stability, opportunity and access to care for at-risk children and over a million parents who rely on it to stay in the workforce. Communities nationwide depend on it as a cornerstone of their child and family support systems.
Head Start works. Not because it's easy — but because it's essential. It's a federal program with decades of data, bipartisan support and consistent, community-driven results. It combines local donations with state and federal funds to provide exactly what Nebraska families need: dependable, comprehensive quality child care.
Given Head Start's proven return and essential impact, the conversations in Congress and in our communities should be about increasing funding, not eliminating it. The return on investment is clear.
Nobel Laureate economist James Heckman found that every dollar invested in quality early childhood programs like Head Start returns more than seven dollars in reduced crime, improved health and increased earnings. Supporting Head Start is not just a moral imperative. It's a smart economic one.
How much does the country invest? Head Start funding accounts for 0.18% of the FY2024 federal budget.
Head Start funding strengthens our work as long-standing early childhood partners in Nebraska. We know these families. We work alongside them. We see the deep commitment to their children and their dreams for their families' futures, many of which would not be possible without help from Head Start.
As a state that values hard work, personal responsibility and community, Nebraskans should encourage congressional support for this invaluable program. When we talk about Nebraska family values, we do not abandon our youngest citizens when they need us most.
We call on our elected officials, neighbors, friends and fellow Nebraskans — from Lincoln to Scottsbluff, Omaha to Ogallala — to speak up. Let your voice be heard. Speak up. Share this message. Remind Washington that Nebraska protects its children.
Let's ensure that, as Head Start celebrates 60 years of impact this May, the gift we give back is unwavering support. Because when we invest in children, we invest in us all.
Sarah Ann Kotchian is chief executive officer of the Nebraska Early Childhood Collaborative. She has served on local and state commissions, task forces and boards.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
2 hours ago
- The Hill
Want safer communities? Protect and expand Medicaid
The debate around public safety is overly focused on policing, prosecution and punishment. One of the most effective tools for building safer communities — Medicaid, known as Medi-Cal in California — is on the chopping block in Congress's proposed budget. Medicaid isn't just a health care program; it funds mental health and substance use treatment. Accordingly, it's a cornerstone of public safety infrastructure. Research shows that when people have access to health coverage through Medicaid, communities experience fewer crimes, fewer incarcerations and less strain on emergency systems. The reverse is also true: Cuts to Medicaid have negative consequences for public safety. So, a Senate-passed budget that puts nearly $1 trillion in Medicaid funding on the chopping block doesn't just threaten health care, it also jeopardizes progress on public safety. As two people with experience in criminal justice reform, we see the connection between health care access and safer communities. When people reentering society receive addiction treatment services, mental health services and even basic health care, they can focus on completing their education, securing a job and reuniting with their families. These are all key strategies for reducing recidivism — ensuring people don't end up back in the prison system after they are released. Our friend Alex is a formerly incarcerated man who now works to help others like him sign up for Medicaid. For him, it's more than a job — it's a lifeline. Alex's employment reinforces his own stability, while helping others access the health care they need to stay out of crisis and out of prison. If Congress enacts deep Medicaid cuts, Alex loses his job, and we lose a proven strategy for public safety. We shouldn't dismantle programs that help people rebuild their lives and keep communities safer. History is full of warnings about the impact of health care cuts on public safety. In 2005, Tennessee rolled back Medicaid coverage for over 170,000 low-income residents. Within two years, those counties saw a nearly 17 percent increase in crime. When people lose access to stabilizing care, the risks of crisis — including contact with the justice system — skyrocket. This matters because more than 70 percent of people in jails and prisons today have at least one diagnosed mental health condition or substance use disorder. That's not a coincidence — it's a warning. Without access to care, individuals often end up in emergency rooms, shelters or jail cells. That's our broken health care system manifesting as a public safety failure. Fortunately, we know what works. Under California's CalAIM initiative, Medi-Cal now offers Enhanced Care Management and Community Supports — services designed to stabilize housing, provide mental health and addiction services, and meet people where they are before a crisis occurs. These programs are compassionate, cost-effective and reduce reliance on emergency interventions. This model supports reentry and stabilizes families. When parents have access to health care and the support they need to heal from addiction, trauma or incarceration, their children are less likely to enter the justice system or the foster care systems. To foster an ecosystem of care for those reentering society, the Amity Foundation integrates health care with education programs, group therapy services and employment services — all of which depend on Medicaid to operate. If the proposed cuts become law, Amity's clinics will shut down, jeopardizing the stability their students need to succeed after years of incarceration. Amity's clinics are not unique — millions nationwide could lose care if clinics close their doors. Medicaid is public safety. It is prevention. It's de-escalation. It's treatment instead of incarceration. And when designed thoughtfully and implemented intentionally, it gives people a fair shot at stability, health and dignity. But we must protect it. Proposals to scale back Medicaid or impose barriers like work requirements threaten to reverse progress. These policies may sound sensible or tough on wasteful spending, but they make communities less safe by stripping away the supports that prevent crime. If we're serious about safety, we have to be serious about Medicaid. We must see it for what it is: an effective public safety strategy. Handcuffs, courtrooms and prisons can only take public safety so far. Safe communities start with prevention — and that means protecting and investing in Medicaid. Sydney Kamlager-Dove, a Democrat, represents California's 37th Congressional District (in Los Angeles) in the U.S. House of Representatives. Doug Bond is CEO of Amity Foundation, with locations in the 37th District. Together, they have collaborated on justice reform efforts focused on reducing incarceration and improving reentry outcomes in California.

Business Upturn
3 hours ago
- Business Upturn
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
Business Wire India Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI.3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved. Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established4,5,6,7,8, particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle.4,5,6,7,8 Key Findings: Ovarian Response: Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy Clinical Pregnancy Rates: Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa Drug Product Usage: After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU) After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU) OHSS Rates: Early OHSS rates were low (2.5% for follitropin delta and 3.0% for follitropin alfa), with no cycle cancellations due to excessive ovarian response on either arm of the study. Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: "No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta." Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities." About GnRH protocols Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI.7,8 About Follitropin Delta (Rekovelle®) Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response.3 It is the first rFSH derived from a human cell line (PER.C6® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins.3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman's AMH level and body weight.3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio.3 About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at or connect with us on LinkedIn, Instagram, YouTube, Facebook and X. REFERENCES 1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020 2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022 3 – Clinical page: (Accessed June 2025) 4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396. 5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482. 6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17. 7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29. 8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash

Indianapolis Star
6 hours ago
- Indianapolis Star
Defunding Planned Parenthood won't stop virtual abortions in Indiana
The years since Roe v. Wade was overturned have been a financial nightmare for Planned Parenthood clinics. Pro-life strategists successfully lobbied for Indiana to eliminate the licenses of abortion clinics in the state; South Carolina to ban Planned Parenthood from receiving Medicaid reimbursements; Congress to vote on divesting from the organization in its budget reconciliation bill and much more. Harming Planned Parenthood, to them, translates to life for countless unborn babies. However, many activists have failed to realize the internet has done far more to perpetuate abortion than they have to end it. If pro-life activists want to end abortion, they need to turn their attention where most abortions are actually happening – through pills prescribed via telehealth. State abortion bans don't stop abortion. Around 9,500 women left Indiana to obtain an abortion last year, and at least 146 abortions were performed in state. For context, there were only 9,529 abortions reported in 2022, the year Indiana's abortion ban took effect. It is worth asking, then, how abortions are happening. KFF Health News estimates that in June 2024, 220 out of 230 abortions obtained by women from Indiana were prescribed via telehealth, despite the fact that doing so is supposed to be illegal. Several surrounding states, including Illinois, have shield laws that hide out-of-state doctors from accountability. The vast majority of all abortions nationwide occur via pill, and a quarter of those cases are the results of telehealth prescriptions. It's reasonable to assume the proportion is larger in states with abortion bans, like Indiana. It's legal under federal law to prescribe the abortion pill via telehealth, for patients to order the pills online and to receive them via taxpayer-subsidized mail, leaving next to no reason for people to go in person to abortion clinics like Planned Parenthood. It's much cheaper and less risky to use the internet. In fact, some have successfully ordered the drug without a medical professional even verifying key eligibility requirements. Abortion pills prescribed via telehealth and delivered by mail are the future of the abortion industry. As such, the role of interstate commerce makes it extremely difficult for any individual state to regulate abortions without criminalizing the women who receive them, which no state with an abortion ban has seen morally fit or politically savvy to do. The Comstock Act, passed over a century ago, banned the use of the U.S. Postal Service to deliver obscene materials, including abortion pills. With Dobbs. v. Jackson Women's Health Organization clarifying that abortion is not a constitutional right, President Trump could simply start enforcing it again if he wanted to take a major swipe at the new, virtual abortion industry. Congress could also ban the use of telehealth to prescribe abortions at a federal level, or the FDA could correctly rule the abortion pill is unsafe for women or babies, following RFK Jr.'s promise to review the safety of the drug. Of course, Trump threw off decades of precedent to push the GOP to oppose pro-life policies at a federal level with the public support of several leaders of supposedly pro-life organizations, so it's unlikely national leaders that ran on being pro-life will step in anytime soon. In the meantime, the new, virtual abortion industry will thrive, even if the financial woes of Planned Parenthood clinics eventually lead to their demise.